Sun Pharma Signs Global Licensing Deal with LIB Therapeutics for Lerodalcibep
Sun Pharma partners with LIB Therapeutics for global licensing of Lerodalcibep, targeting a US$3.7 billion PCSK9 inhibitor market excluding the US and China.
Monday, 28 September 2026
NSE & BSE filings, as they land
ALFA News
Straight from the exchange filing